Skip to main content

Table 8 LNM rate of patients selected by the indications of ESD/EMR

From: The risk of lymph node metastasis in gastric cancer conforming to indications of endoscopic resection and pylorus-preserving gastrectomy: a single-center retrospective study

Conditions

LNM-

LNM+

Metastasis rate

Absolute indication of EMR or ESDa

22

0

0%

Absolute indication of ESD 1a

8

2

20%

Absolute indication of ESD 2a

29

0

0%

Expanded indicationa

10

4

28.57%

T1b, ≤2 cm, differentiated-type

25

2

7.40%

T1b, ≤2 cm, undifferentiated-type

21

11

34.375%

  1. Absolute indication of ESD 1: A differentiated-type adenocarcinoma without ulcerative findings, in which the depth of invasion is clinically diagnosed as T1a and the diameter is > 2 cm
  2. Absolute indication of ESD 2: A differentiated-type adenocarcinoma with ulcerative findings, in which the depth of invasion is clinically diagnosed as T1a and the diameter is ≤3 cm
  3. Expanded indication: An undifferentiated-type adenocarcinoma without ulcerative findings in which the depth of invasion is clinically diagnosed as T1a and the diameter is ≤2 cm
  4. LNM lymph node metastasis, LNM- absence of lymph node metastasis, LNM+ presence of lymph node metastasis, EMR endoscopic mucosal resection, ESD endoscopic submucosal dissection
  5. aAbsolute indication of EMR or ESD: A differentiated-type adenocarcinoma without ulcerative findings (UL0), in which the depth of invasion is clinically diagnosed as T1a and the diameter is ≤2 cm